Interim Data on Cirius Therapeutics’ MSDC-0602K to be Presented at the American Diabetes Association Scientific Sessions

June 5, 2019 - Cirius Therapeutics announced today that results from an interim analysis of exploratory endpoints from its Phase 2bEMMINENCE trial of MSDC-0602K will be presented at the American Diabetes Association 79 Scientific Sessions.

Read More